Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CPA3 | P15088 | 3/20 | 0.64 |
| ▸ | CPA1 | P15085 | 6/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.58 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30239113 | 0.98 | FOLH1 (0.68) | FOLH1CYP1A2CPA3CPA1CPB2 | |
| SCHEMBL4016996 | 0.93 | FOLH1 (0.66) | FOLH1CYP1A2CPA3CPA1CPB2 | |
| SCHEMBL4023050 | 0.93 | FOLH1 (0.66) | FOLH1CYP1A2CPA3CPA1CPB2 | |
| SCHEMBL4017000 | 0.93 | FOLH1 (0.66) | FOLH1CYP1A2CPA3CPA1CPB2 | |
| SCHEMBL2589028 | 0.89 | CYP1A2 (0.70) | FOLH1CYP1A2CPA3CPA1CPB2 | |
| SCHEMBL11664393 | 0.89 | FOLH1 (0.79) | FOLH1CYP1A2CPA3CPA1CPB2 | |
| SCHEMBL28741101 | 0.85 | CPB2 (0.55) | FOLH1CYP1A2CPA3CPB2CPB1 | |
| SCHEMBL27880109 | 0.85 | FOLH1 (0.51) | FOLH1CYP1A2CPA3CPB2 | |
| SCHEMBL19821208 | 0.85 | CYP1A2 (0.83) | FOLH1CYP1A2CPA3CPA1CPB2 | |
| SCHEMBL6724759 | 0.85 | CYP1A2 (0.83) | FOLH1CYP1A2CPA3CPA1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 571 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980843-B2 | Leptin agonist and methods of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-17 | — | — | US | claimed |
| US-20260146293-A1 | METHODS OF DETECTING PROSTATE CANCER | IMMUNIS.AI, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4746895-A1 | A PEPTIDE COMPOSITION AND USES THEREOF | OPTM.RX Ltd (IL) | 2026-05-27 | — | — | EP | disclosed |
| EP-4687986-A1 | PEPTIDE TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | Interna Therapeutics Ltd. (IL) | 2026-02-11 | — | — | EP | disclosed |
| EP-4689188-A2 | ACTIVE SURVEILLANCE AND RISK STRATIFICATION FOR PROSTATE CANCER | Immunis.AI, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260021158-A1 | GRANULAR COMPOSITIONS COMPRISING A PEPTIDE AND USES THEREOF | Tarsier Pharma Ltd (IL) | 2026-01-22 | — | — | US | disclosed |
| US-12529109-B2 | Methods of detecting prostate cancer | IMMUNIS.AI, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346939-A1 | Method of Making Proteins with Non-Standard Amino Acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | disclosed |
| US-12421279-B2 | Cyclic peptide antiviral agents and methods using same | DREXEL UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250237654-A1 | METHODS OF DETECTING PROSTATE CANCER | IMMUNOMDX, INC. | 2025-07-24 | — | — | US | disclosed |
| US-5466797-A | Intermediates for the preparation of cyclic urea | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995029892-A1 | HYDROXAMIC ACID AND AMINO ACID DERIVATIVES AND THEIR USE AS ANTI-ARTHRITIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995023811-A1 | NOVEL CARBOCYCLIC COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION BY INTERACTION WITH THE GPIIB/IIIA RECEPTOR COMPLEX | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995010506-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-20 | — | — | WO | disclosed |
| WO-1994022840-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022910-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994019329-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
| WO-1994008607-A1 | NOVEL PSEUDOPEPTIDE BRADYKININ RECEPTOR ANTAGONISTS | SCIOS NOVA INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1993000359-A1 | MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12529109-B2 | Methods of detecting prostate cancer | DDX3X, DDX5, TMEM205 | FOLH1 120/4885CYP1A2 4641/4885CPA3 271/4885 |
| US-20260021158-A1 | GRANULAR COMPOSITIONS COMPRISING A PEPTIDE AND USES THEREOF | UACA, MAPT, IAPP | FOLH1 353/4885CYP1A2 4806/4885CPA3 152/4885 |
| US-12421279-B2 | Cyclic peptide antiviral agents and methods using same | ZC3HAV1, VIP, LNPEP | FOLH1 466/4885CYP1A2 4869/4885CPA3 102/4885 |
| US-20260146293-A1 | METHODS OF DETECTING PROSTATE CANCER | KLK3, MKI67, MYADM | FOLH1 105/4885CYP1A2 4335/4885CPA3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.